80% of our workforce have a PhD
As recognised by the Government’s Disability Confident scheme, we’re a Level 2 Disability Confident Employer
Our Vision
Working together to be the leading partner for the development and manufacture of new medicines.
Our Mission
We break down the silos in small molecules and new modalities CMC development to accelerate the delivery of life-changing medicines to patients in need.
What we believe in
Getting it right the first time, every time
We assign the best and most suited team to guarantee that every project gets the same attention and right support, no matter the size of your project or company.
Perfect-for-purpose solutions for every project
We exploit our in-depth understanding of the challenges of drug development and leverage our end-in-mind approach to expedite the progress of your assets.
Meeting your expectations is our absolute focus
We provide superlative project and portfolio management through dedicated technical and account leads who are involved at every stage of the process to ensure you meet your objectives.
Our Story
CatSci Ltd was formed in December 2010, after the founders saw an opportunity in the market for a unique catalyst screening company. CatSci was consequently spun out of AstraZeneca’s Catalyst Screening Facility, replicating the same high laboratory standards and experimental workflows. We soon enhanced our offering to provide end-to-end, perfect-for-purpose process research and development services for emerging, mid-sized and large pharma organisations worldwide.
CatSci has since developed into the fully integrated innovation partner for medicines development that it is today. Our fully integrated chemical development, material science, preformulation, GMP analytical, HPAPIs and new modalities teams leverage their extensive knowledge across the CMC landscape and refined workflows based on world-leading approaches that have evolved over years of experience with large pharma. This allows us to deliver complex projects on time and to the requisite quality. In 2020, we created a network of trusted partners across the pharmaceutical supply chain to add strategic value to our customers’ projects throughout the journey from molecule to medicine. In 2021, we opened our second facility in Dagenham, a Centre of Excellence for GMP analytical science that includes small molecules, TACS, glues, oligonucleotides and other complex synthetic medicines. In 2022, we received investment from Keensight Capital to support the expansion of our workforce, laboratories and offering so that we can continuously offer more and better to our customers. We opened our SafeBridge®-certified HPAPI laboratory to address High Potency API development project demands. In 2023, we partnered with AGC Pharma Chemicals Europe, a global CDMO with a proven track record, to offer our customers scalable small molecule API manufacturing from grams to tonnes. In 2023, we also opened our dedicated oligonucleotides laboratory to expedite and de-risk the development and manufacture of RNA therapies.
In 2024, CatSci acquired Reach Separations to offer expert end-to-end chromatographic support from discovery to manufacture.
Our Future
CatSci is constantly evolving to ensure that the demands of modern drug development can be addressed with state-of-the-art technology and moving forward, aligning itself towards the fourth industrial revolution: CatSci 4.0.
We want to be a “Digital First, Intelligent Automation Next company”, freeing up the hands and minds of our talented scientists to solve your drug development challenges.
We will exploit the data we produce and combine it with externally sourced knowledge and information – taking full advantage of any new developments in our space and beyond – to optimise the work that we do to efficiently and effectively deliver innovative solutions for our customers.
Our Milestones
The CatSci Team
We pride ourselves in hiring only the brightest postgraduate or postdoctoral chemists with a high level of technical expertise and a passion for solving multi-disciplinary problems. We stay informed of all requisite science and technology, including process chemistry, material science, preformulation, analytical development, high potency API development, small molecule sustainable manufacturing, catalysis, green chemistry and oligonucleotide R&D and manufacturing. We always assign the best and most suited team for every project, allowing us to bring you access to the best chemistry, alongside excellent project management. This ensures seamless progress from project initiation through to delivery.
The positive outcome of the ‘CatSci Way’ is reflected in the multiple awards that we have won since launching in 2010. Recent recognition includes the 2024 Finance Awards Wales (ESG Excellence), the 2023 UK Fast Growth 50 Index Award (Innovative Growth), the highly esteemed Queen’s Award for Enterprise: International Trade 2022, the 2022 Bionow Awards (Export of the Year), the 2022 Inspire Business Awards (Business of the Year (25+ employees)), the 2022 Wales Business Awards (Workplace Wellbeing), the 2022 Wales STEM Awards (STEM Company of the Year (50+ Employees) and STEM Ambassador of the Year), and the 2022 Cardiff Business Award (International Business of the Year). Further accolades include the CPhI Award in the ‘Excellence in Pharma: Contract Services and Outsourcing’ category in 2018, the Cardiff Business Awards in 2019 (International Business of the Year), the Wales STEM Awards in 2020 (Scale-Up of the Year), and a Top Ten listing within the top ten of the Alantra Pharma Fast 50 awards in 2021. On an individual level, CatSci’s CEO Dr Ross Burn was included in The Medicine Maker’s 2021 Power List of inspirational pharma professionals.
80% of our workforce have a PhD
As recognised by the Government’s Disability Confident scheme, we’re a Level 2 Disability Confident Employer
-
Board of Directors
-
Technical Directors
-
Extended Leadership
